• 1
    Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993; 71(3 Suppl): 108997.
  • 2
    Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 41924.
  • 3
    Wang G, Reed E, Li QQ. Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 2004; 14(1): 2334.
  • 4
    Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32(4): 28493.
  • 5
    Cho SD, Jiang C, Malewicz B et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004; 3(5): 60511.
  • 6
    Cho SD, Ahn NS, Jung JW et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev 2006; 15(1): 5763.
  • 7
    Hansen PE. Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 1994; 75(Suppl 2): 812.
  • 8
    Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 1979; 24: 912.
  • 9
    Wankya BM, Awadh S, Mwai SJ. Tolfenamic acid and ibuprofen in rheumatoid arthritis: a double-blind cross over study. East Afr Med J 1981; 58(8): 6225.
  • 10
    Zachariae E, Sylvest J. Osteoarthritis of the knee treated with tolfenamic acid. Scand J Rheumatol 1972; 1(3): 979.
  • 11
    Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98(12): 85568.
  • 12
    Abdelrahim M, Baker CH, Abbruzzese JL et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007; 67(7): 328694.
  • 13
    Lee SH, Bahn JH, Choi CK et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008; 7(12): 373950.
  • 14
    Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005; 348: 111.
  • 15
    Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 2006; 25(53): 7096105.
  • 16
    Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-3′-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 2003; 133(Suppl 7): 2448S55S.
  • 17
    Yuan H, Gong A, Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005; 26(4): 793801.
  • 18
    Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67(6): 281623.
  • 19
    Huang CS, Ho WL, Lee WS et al. SP1-regulated p27/Kip1 gene expression is involved in terbinafine-induced human A431 cancer cell differentiation: an in vitro and in vivo study. Biochem Pharmacol 2008; 75(9): 178396.
  • 20
    Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008; 62(3): 4449.
  • 21
    Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3(4): 32330.
  • 22
    Colon J, Basha MR, Madero-Visbal R et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011; 29: 4151.
  • 23
    Konduri S, Colon J, Baker CH et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009; 8(3): 53342.
  • 24
    Papineni S, Chintharlapalli S, Abdelrahim M et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30(7): 1193201.